The best indicator for Charles River Laboratories (CRL)
We backtested 20 indicators across daily, weekly and hourly charts on real Charles River Laboratories (CRL) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
CCI
On the daily chart, this is the strongest risk-adjusted edge we found for Charles River Laboratories (CRL) over ~25.9 years — trailing buy-and-hold by 0.1% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | CCI ✓ | Daily | 8.4% | 0.47 | -76.2% | 77.2% | 127 | -0.1% |
| 2 | CCI ✓ | Weekly | 6.5% | 0.39 | -62.3% | 81.5% | 27 | -2.0% |
| 3 | Williams %R ✓ | Weekly | 5.9% | 0.37 | -70.3% | 87.5% | 32 | -2.5% |
| 4 | WaveTrend (8/6/4) ✓ | Daily | 6.2% | 0.36 | -71.0% | 69.1% | 97 | -2.3% |
| 5 | MACD ✓ | Weekly | 5.2% | 0.34 | -57.2% | 45.3% | 53 | -3.3% |
| 6 | Donchian Midline ✓ | Daily | 4.8% | 0.32 | -54.9% | 40.1% | 337 | -3.7% |
| 7 | Holy Grail Confluence ✓ | Daily | 4.5% | 0.31 | -73.2% | 73.7% | 38 | -3.9% |
| 8 | Bollinger Mean-Reversion ✓ | Weekly | 4.0% | 0.3 | -63.1% | 84.2% | 19 | -4.4% |
| 9 | Stochastic ✓ | Daily | 4.2% | 0.29 | -69.0% | 71.6% | 134 | -4.3% |
| 10 | WaveTrend (8/6/4) | Weekly | 4.0% | 0.29 | -71.2% | 89.5% | 19 | -4.4% |
| 11 | EMA 50/200 Cross ✓ | Daily | 3.4% | 0.26 | -54.2% | 37.5% | 16 | -5.1% |
| 12 | Rate of Change ✓ | Daily | 2.8% | 0.24 | -60.6% | 41.7% | 396 | -5.6% |
| 13 | EMA-10 Trend ✓ | Daily | 2.9% | 0.24 | -61.6% | 41.4% | 601 | -5.6% |
| 14 | SMA 50/200 Cross ✓ | Daily | 2.6% | 0.23 | -50.7% | 50.0% | 18 | -5.9% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Charles River Laboratories (CRL), CCI on the daily timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.